DelveInsight’s, “Interstitial Lung Diseases Pipeline Insight 2023” report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in the Interstitial Lung Disease pipeline landscape. It covers the Interstitial Lung Diseases pipeline drug profiles, including Interstitial Lung Diseases clinical trials and nonclinical stage products. It also covers the Interstitial Lung Diseases therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Interstitial Lung Disease Pipeline Report
- DelveInsight’s interstitial lung disease Pipeline report depicts a robust space with 120+ active players working to develop 120 + pipeline therapies for interstitial lung disease treatment.
- The leading Interstitial Lung Diseases Companies include AdAlta, Bristol-Myers Squibb, aTyr Pharma, Avalyn Pharmaceuticals, Beijing Continent Pharmaceutical, Regend Therapeutics, Reata Pharmaceuticals, FibroGen, PureTech Health, Bellerophon Pulse Technologies, OncoArendi Therapeutics, LTT Bio-Pharma, EmphyCorp, Genentech, Cudetaxestat, Boehringer Ingelheim, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Bristol-Myers Squibb, Avalyn Pharma, PureTech Health, Roche, Ark Biosciences, Novartis, Lung Therapeutics, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Taiho Pharmaceutical,Syndax Pharmaceuticals, Metagone Biotech, Galecto Biotech, CSL Behring and AstraZeneca, and others.
- Promising Interstitial Lung Diseases Pipeline Therapies include AD-214, Abatacept, ATYR1923, Pirfenidone inhalation, RO-0220912, Lung stem cells, Bardoxolone methyl, Pamrevlumab, Deupirfenidone, INOpulse, OATD 01, LT 0011, GDC 3280, Blade Therapeutics, BI 1015550, PRA 023, Yifenidone, Riociguat, Treprostinil Palmitil, BMS 986278, Pirfenidone inhalation, Deupirfenidone, Zinpentraxin alfa, AK 3280, Ianalumab, LTI-03, HZN-825, Tipelukast, ENV-101, PLN-74809, KD025, Setanaxib, TAS-115,Axatilimab, MG-S-2525, GB0139,CSL312 and Saracatinib, others.
- November 2023: aTyr Pharma Inc. announced a study of Phase 2 clinical trials for efzofitimod 450 mg. This is a double-blind, randomized, placebo-controlled, PoC study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with SSc-ILD. The primary objective of the study is to evaluate the PoC for efficacy in a population with SSc-ILD. While improvement of ILD is the outcome of interest, the study will also evaluate changes in the skin. After initial screening (up to 4 weeks), approximately 25 eligible participants will be randomized 2:2:1 to 1 of 2 active (experimental) dose arms or placebo, administered every 4 weeks up to and including Week 20.
- November 2023: Prometheus Biosciencese Inc. announced a study of Phase 2 clinical trials for PRA023 IV. The purpose of this study is to assess the safety and efficacy of PRA023 in participants with SSc-ILD.
- November 2023: Insmed Incorporated announced a study of Phase 2 & 3 clinical trials for Treprostinil Palmitil Inhalation Powder. The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-211 (NCT05176951) and other lead-in studies of TPIP in participants with PH-ILD.
Request a sample and discover the recent breakthroughs happening in the Interstitial Lung Disease Pipeline landscape @ Interstitial Lung Disease Pipeline Outlook
In the Interstitial Lung Disease Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Interstitial Lung Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Interstitial Lung Disease Overview
Interstitial lung disease (diffused parenchymal diseases) are a heterogeneous group of disorders characterized by fibrosis (scarring) of the lungs. These are classified on the basis of histopathological, radiologic and clinical parameters. The classification system used to describe interstitial lung disease categorizes conditions based on clinical, histopathological or radiologic parameters. Clinical classification groups ILD by its causes to help differentiate exogenous or endogenous factors.
Find out more about Interstitial Lung Disease Therapeutics Assessment @ Interstitial Lung Disease Preclinical and Discovery Stage Products
Interstitial Lung Disease Emerging Drugs Profile
- DWN12088: Daewoong Pharmaceutical
- LYT-100: PureTech
- BMS-986278: Bristol-Myers Squibb
Interstitial Lung Disease Pipeline Therapeutics Assessment
There are approx. 120+ key companies which are developing the therapies Interstitial Lung Disease. The Interstitial Lung Disease companies which have their Interstitial Lung Disease drug candidates in the most advanced stage, i.e phase III include Pfizer.
DelveInsight’s Interstitial Lung Disease Pipeline Report covers around 120+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Interstitial Lung Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
Interstitial Lung Disease Pipeline Products have been categorized under various Molecule types such as
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
Learn more about the emerging Interstitial Lung Disease Pipeline Therapies @ Interstitial Lung Disease Clinical Trials Assessment
Scope of the Interstitial Lung Disease Pipeline Report
- Coverage- Global
- Interstitial Lung Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Interstitial Lung Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Interstitial Lung Disease Companies- AdAlta, Bristol-Myers Squibb, aTyr Pharma, Avalyn Pharmaceuticals, Beijing Continent Pharmaceutical, Regend Therapeutics, Reata Pharmaceuticals, FibroGen, PureTech Health, Bellerophon Pulse Technologies, OncoArendi Therapeutics, LTT Bio-Pharma, EmphyCorp, Genentech, Cudetaxestat, Boehringer Ingelheim, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Bristol-Myers Squibb, Avalyn Pharma, PureTech Health, Roche, Ark Biosciences, Novartis, Lung Therapeutics, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Taiho Pharmaceutical,Syndax Pharmaceuticals, Metagone Biotech, Galecto Biotech, CSL Behring and AstraZeneca, and others.
- Interstitial Lung Disease Pipeline Therapies- AD-214, Abatacept, ATYR1923, Pirfenidone inhalation, RO-0220912, Lung stem cells, Bardoxolone methyl, Pamrevlumab, Deupirfenidone, INOpulse, OATD 01, LT 0011, GDC 3280, Blade Therapeutics, BI 1015550, PRA 023, Yifenidone, Riociguat, Treprostinil Palmitil, BMS 986278, Pirfenidone inhalation, Deupirfenidone, Zinpentraxin alfa, AK 3280, Ianalumab, LTI-03, HZN-825, Tipelukast, ENV-101, PLN-74809, KD025, Setanaxib, TAS-115,Axatilimab, MG-S-2525, GB0139,CSL312 and Saracatinib, others.
Dive deep into rich insights for drugs for Interstitial Lung Disease Pipeline Companies and Therapies, click here @ Interstitial Lung Disease Unmet Needs and Analyst Views
Table of Content
- Introduction
- Interstitial Lung Disease Executive Summary
- Interstitial Lung Disease: Overview
- Interstitial Lung Disease Pipeline Therapeutics
- Interstitial Lung Disease Therapeutic Assessment
- Interstitial Lung Disease– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- RO-0220912: Roche
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Daratumumab: Janssen Biotech
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- BGB 16673: BeiGene
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Interstitial Lung Disease Key Companies
- Interstitial Lung Disease Key Products
- Interstitial Lung Disease- Unmet Needs
- Interstitial Lung Disease- Market Drivers and Barriers
- Interstitial Lung Disease- Future Perspectives and Conclusion
- Interstitial Lung Disease Analyst Views
- Interstitial Lung Disease Key Companies
- Appendix
For further information on the Interstitial Lung Disease Pipeline therapeutics, reach out to Interstitial Lung Disease Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/acne-vulgaris-av-market